CHICAGO — Adicet Bio reported Monday that a unique, off-the-shelf therapy made from a special type of T cell induced complete remissions in patients with advanced and aggressive B-cell lymphomas, including patients with cancer who relapsed after receiving a personalized CAR-T treatment.
In the early-stage study, six of eight patients achieved complete remissions after a single infusion of Adicet’s therapy, called ADI-001. Three of the patients were particularly difficult to treat because they entered the study with lymphomas that had relapsed after they received CAR-T treatments; all achieved complete remissions with ADI-001, Adicet said.